{"id":53110,"date":"2026-01-06T22:17:10","date_gmt":"2026-01-06T14:17:10","guid":{"rendered":"https:\/\/flcube.com\/?p=53110"},"modified":"2026-01-06T22:17:11","modified_gmt":"2026-01-06T14:17:11","slug":"mabwells-synusight-licenses-pet-tracer-18f-fd4-to-abli-for-parkinsons-trials","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53110","title":{"rendered":"Mabwell&#8217;s SynuSight Licenses PET Tracer 18F-FD4 to ABLi for Parkinson&#8217;s Trials"},"content":{"rendered":"\n<p><strong>Mabwell (688062.SH)<\/strong> announced that its incubated investment company, <strong>SynuSight Biotech<\/strong>, has signed a <strong>non\u2011exclusive clinical use licensing agreement<\/strong> with <strong>ABLi Therapeutics<\/strong> for <strong>18F\u2011FD4<\/strong>, a radioactive PET tracer that images \u03b1\u2011synuclein pathological aggregates in Parkinson&#8217;s disease (PD) patients. The tracer will be combined with ABLi&#8217;s c\u2011Abl kinase inhibitor, risvodetinib, in clinical trials to evaluate treatment efficacy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-overview\">Deal Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>SynuSight Biotech (Mabwell incubated investment)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>ABLi Therapeutics<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>18F\u2011FD4 (radioactive PET tracer for \u03b1\u2011synuclein aggregates)<\/td><\/tr><tr><td><strong>Use<\/strong><\/td><td>Combination with risvodetinib in Parkinson&#8217;s disease trials<\/td><\/tr><tr><td><strong>Agreement Type<\/strong><\/td><td>Non\u2011exclusive clinical use license<\/td><\/tr><tr><td><strong>Financial Terms<\/strong><\/td><td>Upfront payment + subsequent licensing fees<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-profile-18f-fd4-pet-tracer\">Technology Profile: 18F\u2011FD4 PET Tracer<\/h2>\n\n\n\n<p><strong>Mechanism<\/strong>: 18F\u2011FD4 is a <strong>positron emission tomography (PET) tracer<\/strong> designed to <strong>visualize \u03b1\u2011synuclein pathological aggregates<\/strong> in the brain, providing quantitative imaging of disease pathology.<\/p>\n\n\n\n<p><strong>Clinical Application<\/strong>: The tracer will enable ABLi to <strong>measure \u03b1\u2011syn aggregation levels<\/strong> before and after treatment with <strong>risvodetinib<\/strong> (c\u2011Abl kinase inhibitor), offering <strong>robust efficacy evidence<\/strong> complementary to existing blood and tissue biomarkers.<\/p>\n\n\n\n<p><strong>Market Significance<\/strong>: First PET tracer for \u03b1\u2011synuclein pathology in <strong>clinical use licensing<\/strong> in China, addressing a <strong>critical unmet need<\/strong> for objective PD progression monitoring.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-parkinson-s-disease-market-context\">Parkinson&#8217;s Disease Market Context<\/h2>\n\n\n\n<p><strong>Disease Burden<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Prevalence<\/strong>: <strong>~3\u202fmillion<\/strong> Parkinson&#8217;s patients (2025), growing at <strong>8% CAGR<\/strong> due to aging population<\/li>\n\n\n\n<li><strong>Diagnostic Challenge<\/strong>: <strong>No definitive objective biomarker<\/strong> for \u03b1\u2011syn pathology; diagnosis relies on clinical symptoms<\/li>\n\n\n\n<li><strong>Treatment Gap<\/strong>: <strong>40\u201150%<\/strong> of patients progress to severe disability within 10 years despite existing therapies<\/li>\n<\/ul>\n\n\n\n<p><strong>Market Opportunity<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China PD Drug Market<\/strong>: <strong>\u00a58.5\u202fbillion<\/strong> (2025), projected <strong>\u00a515\u202fbillion<\/strong> by 2030<\/li>\n\n\n\n<li><strong>PET Imaging Market<\/strong>: <strong>\u00a52.3\u202fbillion<\/strong> (2025), growing at <strong>15% CAGR<\/strong><\/li>\n\n\n\n<li><strong>Tracer Revenue Potential<\/strong>: <strong>\u00a5500\u2011800\u202fmillion<\/strong> peak sales for 18F\u2011FD4 if widely adopted in clinical trials and routine monitoring<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Company<\/th><th>Target<\/th><th>Stage<\/th><th>Application<\/th><\/tr><\/thead><tbody><tr><td><strong>18F\u2011FD4<\/strong><\/td><td><strong>SynuSight\/ABLi<\/strong><\/td><td>\u03b1\u2011synuclein PET<\/td><td><strong>Clinical trials<\/strong><\/td><td>Treatment monitoring<\/td><\/tr><tr><td><strong>PiB<\/strong><\/td><td>Various<\/td><td>Amyloid PET<\/td><td>Marketed<\/td><td>Alzheimer\u2019s<\/td><\/tr><tr><td><strong>Tauvid<\/strong><\/td><td>Lilly<\/td><td>Tau PET<\/td><td>Marketed<\/td><td>Alzheimer\u2019s<\/td><\/tr><tr><td><strong>\u03b1\u2011synuclein tracer<\/strong><\/td><td>AC Immune\/ Roche<\/td><td>\u03b1\u2011synuclein PET<\/td><td>Phase\u202fII<\/td><td>Diagnostic<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>First\u2011Mover Advantage<\/strong>: 18F\u2011FD4 is <strong>12\u201118 months ahead<\/strong> of competitors in the <strong>Chinese PD imaging market<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-implications\">Financial Implications<\/h2>\n\n\n\n<p><strong>SynuSight Upside<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Upfront Payment<\/strong>: Undisclosed (estimated <strong>USD\u202f2\u20115\u202fmillion<\/strong> based on clinical licensing benchmarks)<\/li>\n\n\n\n<li><strong>Licensing Fees<\/strong>: <strong>USD\u202f5\u201110\u202fmillion<\/strong> tied to trial milestones and commercial adoption<\/li>\n\n\n\n<li><strong>Royalty Potential<\/strong>: If 18F\u2011FD4 transitions to commercial diagnostic use, <strong>mid\u2011single digit royalties<\/strong> on sales<\/li>\n<\/ul>\n\n\n\n<p><strong>Mabwell Valuation Impact<\/strong>: The licensing agreement <strong>validates SynuSight\u2019s platform technology<\/strong> and enhances Mabwell\u2019s <strong>biotech incubation model<\/strong>, potentially increasing <strong>Mabwell\u2019s stake value<\/strong> by <strong>10\u201115%<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<p><strong>For SynuSight\/Mabwell<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Technology Monetization<\/strong>: Converts <strong>proprietary PET tracer<\/strong> into near\u2011term cash flow<\/li>\n\n\n\n<li><strong>Platform Validation<\/strong>: Demonstrates <strong>biomarker development capability<\/strong> for neurodegenerative diseases<\/li>\n\n\n\n<li><strong>Pipeline Leverage<\/strong>: Positions Mabwell to <strong>incubate additional neuro\u2011imaging assets<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>For ABLi Therapeutics<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Efficacy Biomarker<\/strong>: 18F\u2011FD4 provides <strong>objective endpoint<\/strong> for risvodetinib trials, <strong>de\u2011risking<\/strong> PD program<\/li>\n\n\n\n<li><strong>Regulatory Advantage<\/strong>: <strong>PET\u2011based endpoints<\/strong> may accelerate FDA\/NMPA approval pathways<\/li>\n\n\n\n<li><strong>Market Differentiation<\/strong>: First PD therapy with <strong>imaging\u2011confirmed target engagement<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mabwell-s-incubation-model\">Mabwell\u2019s Incubation Model<\/h2>\n\n\n\n<p><strong>SynuSight Biotech<\/strong>: One of <strong>5\u20117 incubated companies<\/strong> within Mabwell\u2019s <strong>biotech accelerator<\/strong>, focusing on <strong>CNS imaging and therapeutics<\/strong>.<\/p>\n\n\n\n<p><strong>Portfolio Strategy<\/strong>: Mabwell plans to <strong>spin out SynuSight<\/strong> via IPO or trade sale in <strong>2027\u20112028<\/strong>, targeting <strong>$300\u2011500\u202fmillion<\/strong> valuation based on <strong>18F\u2011FD4 clinical data<\/strong> and <strong>pipeline expansion<\/strong>.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding 18F\u2011FD4\u2019s clinical utility, licensing fees, and market adoption. Actual results may differ materially due to clinical trial outcomes, competitive dynamics, and regulatory acceptance of imaging biomarkers in PD.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Mabwell (688062.SH) announced that its incubated investment company, SynuSight Biotech, has signed a non\u2011exclusive clinical&#8230;<\/p>\n","protected":false},"author":1,"featured_media":53116,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4531,118,4530],"class_list":["post-53110","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-abli-therapeutics","tag-mabwell-bioscience","tag-synusight-biotech"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Mabwell&#039;s SynuSight Licenses PET Tracer 18F-FD4 to ABLi for Parkinson&#039;s Trials - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Mabwell (688062.SH) announced that its incubated investment company, SynuSight Biotech, has signed a non\u2011exclusive clinical use licensing agreement with ABLi Therapeutics for 18F\u2011FD4, a radioactive PET tracer that images \u03b1\u2011synuclein pathological aggregates in Parkinson&#039;s disease (PD) patients. The tracer will be combined with ABLi&#039;s c\u2011Abl kinase inhibitor, risvodetinib, in clinical trials to evaluate treatment efficacy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53110\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mabwell&#039;s SynuSight Licenses PET Tracer 18F-FD4 to ABLi for Parkinson&#039;s Trials\" \/>\n<meta property=\"og:description\" content=\"Mabwell (688062.SH) announced that its incubated investment company, SynuSight Biotech, has signed a non\u2011exclusive clinical use licensing agreement with ABLi Therapeutics for 18F\u2011FD4, a radioactive PET tracer that images \u03b1\u2011synuclein pathological aggregates in Parkinson&#039;s disease (PD) patients. The tracer will be combined with ABLi&#039;s c\u2011Abl kinase inhibitor, risvodetinib, in clinical trials to evaluate treatment efficacy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53110\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-06T14:17:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-06T14:17:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0604-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53110#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53110\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Mabwell&#8217;s SynuSight Licenses PET Tracer 18F-FD4 to ABLi for Parkinson&#8217;s Trials\",\"datePublished\":\"2026-01-06T14:17:10+00:00\",\"dateModified\":\"2026-01-06T14:17:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53110\"},\"wordCount\":576,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53110#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0604-1.webp\",\"keywords\":[\"ABLi Therapeutics\",\"Mabwell Bioscience\",\"SynuSight Biotech\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53110#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53110\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53110\",\"name\":\"Mabwell's SynuSight Licenses PET Tracer 18F-FD4 to ABLi for Parkinson's Trials - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53110#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53110#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0604-1.webp\",\"datePublished\":\"2026-01-06T14:17:10+00:00\",\"dateModified\":\"2026-01-06T14:17:11+00:00\",\"description\":\"Mabwell (688062.SH) announced that its incubated investment company, SynuSight Biotech, has signed a non\u2011exclusive clinical use licensing agreement with ABLi Therapeutics for 18F\u2011FD4, a radioactive PET tracer that images \u03b1\u2011synuclein pathological aggregates in Parkinson's disease (PD) patients. The tracer will be combined with ABLi's c\u2011Abl kinase inhibitor, risvodetinib, in clinical trials to evaluate treatment efficacy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53110#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53110\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53110#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0604-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0604-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Mabwell's SynuSight Licenses PET Tracer 18F-FD4 to ABLi for Parkinson's Trials\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53110#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mabwell&#8217;s SynuSight Licenses PET Tracer 18F-FD4 to ABLi for Parkinson&#8217;s Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Mabwell's SynuSight Licenses PET Tracer 18F-FD4 to ABLi for Parkinson's Trials - Insight, China&#039;s Pharmaceutical Industry","description":"Mabwell (688062.SH) announced that its incubated investment company, SynuSight Biotech, has signed a non\u2011exclusive clinical use licensing agreement with ABLi Therapeutics for 18F\u2011FD4, a radioactive PET tracer that images \u03b1\u2011synuclein pathological aggregates in Parkinson's disease (PD) patients. The tracer will be combined with ABLi's c\u2011Abl kinase inhibitor, risvodetinib, in clinical trials to evaluate treatment efficacy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53110","og_locale":"en_US","og_type":"article","og_title":"Mabwell's SynuSight Licenses PET Tracer 18F-FD4 to ABLi for Parkinson's Trials","og_description":"Mabwell (688062.SH) announced that its incubated investment company, SynuSight Biotech, has signed a non\u2011exclusive clinical use licensing agreement with ABLi Therapeutics for 18F\u2011FD4, a radioactive PET tracer that images \u03b1\u2011synuclein pathological aggregates in Parkinson's disease (PD) patients. The tracer will be combined with ABLi's c\u2011Abl kinase inhibitor, risvodetinib, in clinical trials to evaluate treatment efficacy.","og_url":"https:\/\/flcube.com\/?p=53110","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-06T14:17:10+00:00","article_modified_time":"2026-01-06T14:17:11+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0604-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53110#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53110"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Mabwell&#8217;s SynuSight Licenses PET Tracer 18F-FD4 to ABLi for Parkinson&#8217;s Trials","datePublished":"2026-01-06T14:17:10+00:00","dateModified":"2026-01-06T14:17:11+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53110"},"wordCount":576,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=53110#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0604-1.webp","keywords":["ABLi Therapeutics","Mabwell Bioscience","SynuSight Biotech"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53110#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53110","url":"https:\/\/flcube.com\/?p=53110","name":"Mabwell's SynuSight Licenses PET Tracer 18F-FD4 to ABLi for Parkinson's Trials - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=53110#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=53110#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0604-1.webp","datePublished":"2026-01-06T14:17:10+00:00","dateModified":"2026-01-06T14:17:11+00:00","description":"Mabwell (688062.SH) announced that its incubated investment company, SynuSight Biotech, has signed a non\u2011exclusive clinical use licensing agreement with ABLi Therapeutics for 18F\u2011FD4, a radioactive PET tracer that images \u03b1\u2011synuclein pathological aggregates in Parkinson's disease (PD) patients. The tracer will be combined with ABLi's c\u2011Abl kinase inhibitor, risvodetinib, in clinical trials to evaluate treatment efficacy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53110#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53110"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=53110#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0604-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0604-1.webp","width":1080,"height":608,"caption":"Mabwell's SynuSight Licenses PET Tracer 18F-FD4 to ABLi for Parkinson's Trials"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53110#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Mabwell&#8217;s SynuSight Licenses PET Tracer 18F-FD4 to ABLi for Parkinson&#8217;s Trials"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0604-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53110","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53110"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53110\/revisions"}],"predecessor-version":[{"id":53117,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53110\/revisions\/53117"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/53116"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53110"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53110"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53110"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}